Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Nebiyou Bekele

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Biometrics|July 14, 2005
A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trialB Nebiyou Bekele, Yu Shen
Biometrics|January 29, 2009
Adaptive randomization for multiarm comparative clinical trials based on joint efficacy/toxicity outcomesYuan Ji, B Nebiyou Bekele
Journal of Biopharmaceutical Statistics|February 21, 2018
Controlling alpha for mixed effects models for repeated measuresZhishen Ye, B Nebiyou Bekele
Clinical Trials (London, England)|August 24, 2007
Dose-finding in phase I clinical trials based on toxicity probability intervalsYuan Ji, Yisheng Li, B Nebiyou Bekele
Clinical Trials (London, England)|September 8, 2010
Adaptive dose insertion in early phase clinical trialsBo Hu, B Nebiyou Bekele, Yuan Ji
Biometrics|August 4, 2009
Risk-group-specific dose finding based on an average toxicity scoreB Nebiyou Bekele, Yisheng Li, Yuan Ji
Annals of Epidemiology|April 21, 2009
Bayesian modeling of follow-up studies with missing dataJames D Stamey, B Nebiyou Bekele, Stephanie Powers
Clinical Trials (London, England)|October 12, 2010
A modified toxicity probability interval method for dose-finding trialsYuan Ji, Ping Liu, Yisheng Li, et al.
Statistics in Medicine|June 20, 2008
Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformationYisheng Li, B Nebiyou Bekele, Yuan Ji, et al.
Biostatistics (Oxford, England)|December 18, 2007
Monitoring late-onset toxicities in phase I trials using predicted risksB Nebiyou Bekele, Yuan Ji, Yu Shen, et al.
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Biometrics|July 14, 2005
A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trialB Nebiyou Bekele, Yu Shen
Biometrics|January 29, 2009
Adaptive randomization for multiarm comparative clinical trials based on joint efficacy/toxicity outcomesYuan Ji, B Nebiyou Bekele
Journal of Biopharmaceutical Statistics|February 21, 2018
Controlling alpha for mixed effects models for repeated measuresZhishen Ye, B Nebiyou Bekele
Clinical Trials (London, England)|August 24, 2007
Dose-finding in phase I clinical trials based on toxicity probability intervalsYuan Ji, Yisheng Li, B Nebiyou Bekele
Clinical Trials (London, England)|September 8, 2010
Adaptive dose insertion in early phase clinical trialsBo Hu, B Nebiyou Bekele, Yuan Ji
Biometrics|August 4, 2009
Risk-group-specific dose finding based on an average toxicity scoreB Nebiyou Bekele, Yisheng Li, Yuan Ji
Annals of Epidemiology|April 21, 2009
Bayesian modeling of follow-up studies with missing dataJames D Stamey, B Nebiyou Bekele, Stephanie Powers
Clinical Trials (London, England)|October 12, 2010
A modified toxicity probability interval method for dose-finding trialsYuan Ji, Ping Liu, Yisheng Li, et al.
Statistics in Medicine|June 20, 2008
Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformationYisheng Li, B Nebiyou Bekele, Yuan Ji, et al.
Biostatistics (Oxford, England)|December 18, 2007
Monitoring late-onset toxicities in phase I trials using predicted risksB Nebiyou Bekele, Yuan Ji, Yu Shen, et al.
Pageof 10